Longhorn Vaccines and Diagnostics to Present at Infectious Disease Week 2022

BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics LLC, a One Health and One World company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today announced that it will present two abstracts at Infectious Disease (ID) Week, being in Washington, DC, Oct. 19 – 23, 2022.

The abstracts focus on Longhorn’s work in developing vaccines for a universal influenza vaccine, antimicrobial resistant bacteria, and the company’s work in COVID-19.

Abstract #1
Abstract Title: IgM Monoclonal Antibodies Targeting Peptidoglycan May Provide Therapeutic Strategies against Antimicrobial Resistant Bacteria
Presenter: Clara J. Sei, Director, Microbiology and Immunology at Longhorn Vaccines and Diagnostics
Session Title: Antimicrobial Novel Agents
Session Date: Saturday October 22, 2022
Session Time: 12:15 PM - 1:30 PM
Session Location: Walter E. Washington Convention Center in Exhibit Hall BC

Abstract #2
Abstract Title: A Composite Peptide Vaccine Comprised of Conserved SARS-CoV-2 and Influenza Epitopes Generated Antisera Reponses to Both Coronavirus and Influenza
Presenter: Nimisha Rikhi, Research Scientist at Longhorn Vaccines and Diagnostics
Session Title: Updates on Adult Immunizations
Session Date: Saturday October 22, 2022
Session Time: 1:45 PM - 3:00 PM
Session Location: Walter E. Washington Convention Center in room 144 ABC

Posters will be available to view on the conference platform during the conference. Further information about IDWeek 2022 can be found here.

About Longhorn Vaccines and Diagnostics LLC

Longhorn Vaccines and Diagnostics LLC is a One Health and One World company based in Maryland that is developing vaccines and diagnostic tools for worldwide public health concerns and to prevent future pandemics. Since its inception in 2006, Longhorn has focused on developing vaccines and diagnostic tools that can impact a pandemic on a global scale and at all socio-economic levels. Since pandemics flow between humans and animals, Longhorn caters to both in order to surveil, diagnose, prevent and treat the next infectious disease.

Longhorn’s core product, PrimeStore^® Molecular Transport Medium (MTM), is a patented, FDA cleared, state-of-the-art ambient temperature molecular diagnostic collection and transport device that can help governments, global health organizations, and drug manufacturers improve the diagnosis and treatment of highly infectious diseases such as Influenza, SARS-CoV-2, and Mycobacterium tuberculosis (TB). Unlike standard devices for collecting and transporting virus samples, PrimeStore^® MTM is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory based molecular testing and characterization.